Cibinqo Den Europæiske Union - islandsk - EMA (European Medicines Agency)

cibinqo

pfizer europe ma eeig  - abrocitinib - dermatitis, atópísk - aðrar húðsjúkdómar - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Kairasec Tafla 8 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 8 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 8 mg

Kairasec Tafla 16 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 16 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 16 mg

Candpress Comp Tafla 16 mg/12,5 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

candpress comp tafla 16 mg/12,5 mg

teva b.v.* - candesartanum cílexetíl; hydrochlorothiazide - tafla - 16 mg/12,5 mg

Kairasec Tafla 32 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 32 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg

Entresto Den Europæiske Union - islandsk - EMA (European Medicines Agency)

entresto

novartis europharm limited - sacubitril, valsartan - hjartabilun - ace ii hemla, önnur sturtu, umboðsmenn starfa á renín-ace kerfi - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.